Connecting the dots between Parkinson’s disease and rheumatoid arthritis

NEUROLOGY RHEUMATOLOGY
12 Jul 2023

Get access to our exclusive articles.
Related Articles

Exploring the association of systemic glucocorticoids and incident major adverse cardiovascular events in patients with rheumatoid arthritis based on real-world data

Despite their exceptional anti-inflammatory properties, the use of systemic glucocorticoids (GCs) for the treatment of rheumatoid arthritis (RA) remains controversial due to the potential side effects, particularly their role in elevating patients’ risk of cardiovascular (CV) events. A po
RHEUMATOLOGY
03 Jan 2024

The 2022 updated guidelines for RA

Based on inputs from a global task force on recent systematic literaturereviews (SLRs) regarding rheumatoid arthritis (RA), experts from theEuropean Alliance of Associations for Rheumatology (EULAR) updatedrecommendations for the RA management.1 The previous guidelineswere updated in 2019.2 One main
RHEUMATOLOGY
29 Jul 2022

Baricitinib yields favorable outcomes in JIA: the phase 3 JUVE-BASIS trial
RHEUMATOLOGY
19 Jul 2022

Strong association between high disease activity in rheumatoid arthritis and venous thromboembolism

Over time, it has become clear that rheumatoid arthritis (RA) patients are at increased risk of venous thromboembolism (VTE), such as deep vein thrombosis (DVT) and pulmonary embolism (PE).1 EULAR President Professor Iain McInnes from The University of

RHEUMATOLOGY
31 Aug 2020